<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    2669155
   </pmid>
   <datecreated>
    <year>
     1989
    </year>
    <month>
     09
    </month>
    <day>
     13
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1989
    </year>
    <month>
     09
    </month>
    <day>
     13
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0038-4348
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       82
      </volume>
      <issue>
       8
      </issue>
      <pubdate>
       <year>
        1989
       </year>
       <month>
        Aug
       </month>
      </pubdate>
     </journalissue>
     <title>
      Southern medical journal
     </title>
     <isoabbreviation>
      South. Med. J.
     </isoabbreviation>
    </journal>
    <articletitle>
     Incidence of cardiac arrhythmias associated with mild hypokalemia induced by low-dose diuretic therapy for hypertension.
    </articletitle>
    <pagination>
     <medlinepgn>
      966-9, 976
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      Nineteen men with mild to moderate hypertension and without a history of cardiac arrhythmias were randomized (double-blind) into groups to receive hydrochlorothiazide (HCTZ) at a dose of 25 mg/day, HCTZ at 50 mg/day, or HCTZ (25 mg) plus triamterene (50 mg) for a six-month period after a three-week (single-blind) placebo period. Serum electrolyte values were determined at baseline and at frequent intervals thereafter. Twenty-four hour ambulatory electrocardiograms were obtained at baseline and just before study termination. Mild hypokalemia (less than 3.5 mEq/L) occurred in approximately half of the patients and was unrelated to treatment group. Serious arrhythmias were infrequent, though some patients had large numbers of extra beats. The incidence of arrhythmia appeared unrelated to serum potassium concentration. We conclude that mild hypokalemia associated with low-dose diuretic therapy for hypertension is not arrhythmogenic.
     </abstracttext>
    </abstract>
    <affiliation>
     Medical Service, Veterans Administration Medical Center, Baltimore, MD 21218.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Peters
      </lastname>
      <forename>
       R W
      </forename>
      <initials>
       RW
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hamilton
      </lastname>
      <forename>
       J
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hamilton
      </lastname>
      <forename>
       B P
      </forename>
      <initials>
       BP
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, U.S. Gov't, Non-P.H.S.
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     South Med J
    </medlineta>
    <nlmuniqueid>
     0404522
    </nlmuniqueid>
    <issnlinking>
     0038-4348
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      396-01-0
     </registrynumber>
     <nameofsubstance>
      Triamterene
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      58-93-5
     </registrynumber>
     <nameofsubstance>
      Hydrochlorothiazide
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Arrhythmias, Cardiac
     </descriptorname>
     <qualifiername majortopicyn="Y">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Clinical Trials as Topic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Administration Schedule
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Therapy, Combination
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Electrocardiography
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hydrochlorothiazide
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypertension
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypokalemia
     </descriptorname>
     <qualifiername majortopicyn="Y">
      chemically induced
     </qualifiername>
     <qualifiername majortopicyn="N">
      complications
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Monitoring, Physiologic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Random Allocation
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Triamterene
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1989
     </year>
     <month>
      8
     </month>
     <day>
      1
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1989
     </year>
     <month>
      8
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1989
     </year>
     <month>
      8
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     2669155
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

